JP2004504038A5 - - Google Patents

Info

Publication number

JP2004504038A5

JP2004504038A5 JP2002512419A JP2002512419A JP2004504038A5 JP 2004504038 A5 JP2004504038 A5 JP 2004504038A5 JP 2002512419 A JP2002512419 A JP 2002512419A JP 2002512419 A JP2002512419 A JP 2002512419A JP 2004504038 A5 JP2004504038 A5 JP 2004504038A5

Authority

JP

Japan

Prior art keywords

seq

nucleotide

nos

nucleotides

pkd1

Prior art date

2001-07-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002773 nucleotide Substances 0.000 description 336
• 125000003729 nucleotide group Chemical group 0.000 description 336
• 238000000034 method Methods 0.000 description 57
• 101001074444 Homo sapiens Polycystin-1 Proteins 0.000 description 55
• 102100036143 Polycystin-1 Human genes 0.000 description 55
• 230000003321 amplification Effects 0.000 description 47
• 238000003199 nucleic acid amplification method Methods 0.000 description 47
• 108091033319 polynucleotide Proteins 0.000 description 31
• 239000002157 polynucleotide Substances 0.000 description 31
• 102000040430 polynucleotide Human genes 0.000 description 31
• 230000035772 mutation Effects 0.000 description 28
• 101100029888 Homo sapiens PKD1 gene Proteins 0.000 description 22
• 101150056230 PKD1 gene Proteins 0.000 description 22
• 238000007857 nested PCR Methods 0.000 description 15
• 239000000523 sample Substances 0.000 description 15
• 239000011159 matrix material Substances 0.000 description 12
• 239000013068 control sample Substances 0.000 description 10
• 239000007787 solid Substances 0.000 description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
• 239000013610 patient sample Substances 0.000 description 7
• 238000009396 hybridization Methods 0.000 description 5
• 239000012634 fragment Substances 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000008018 melting Effects 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 238000007865 diluting Methods 0.000 description 2
• 239000000203 mixture Substances 0.000 description 2
• 238000003752 polymerase chain reaction Methods 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 125000003275 alpha amino acid group Chemical group 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 description 1
• 239000003795 chemical substances by application Substances 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
• 238000003795 desorption Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 239000005546 dideoxynucleotide Substances 0.000 description 1
• 201000010099 disease Diseases 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1